Ocugen, Inc (OCGN)

NASDAQ
8.75
+0.52(+6.32%)
After Hours
8.63
-0.12(-1.3714%)
- Real-time Data
  • Volume:
    41,782,063
  • Bid/Ask:
    8.63/8.65
  • Day's Range:
    8.01 - 8.80

OCGN Overview

Prev. Close
8.23
Day's Range
8.01 - 8.8
Revenue
40K
Open
8.25
52 wk Range
0.173 - 18.69
EPS
-0.33
Volume
41,782,063
Market Cap
1.73B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
64,447,372
P/E Ratio
-
Beta
4.58
1-Year Change
2,531.07%
Shares Outstanding
198,228,533
Next Earnings Date
Aug 13, 2021
What is your sentiment on Ocugen, Inc?
or
Market is currently closed. Voting is open during market hours.

Ocugen, Inc News

Ocugen, Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralNeutralSell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellBuy
SummaryStrong BuyStrong BuyBuyNeutralNeutral

Ocugen, Inc Company Profile

Ocugen, Inc Company Profile

Employees
15

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Read More
  • 🐇
    0
    • https://www.change.org/p/federal-drug-administration-covaxin-vaccine-needs-to-be-available-in-the-us?utm_content=cl_sharecopy_28869446_en-US%3A3&recruiter=913402509&recruited_by_id=ba316570-e5b9-11e8-93b8-19b33518b298&utm_source=share_petition&utm_medium=copylink&utm_campaign=psf_combo_share_initial&utm_term=psf_combo_share_initial
      0
      • I'm with u bro
        0
    • Moonshot ?? 💥🚀
      1
      • oh, yes, baby
        1
    • https://ocugen.com/vaccine/news/
      0
      • By Craig Snyder CEO of indigo GlobalThe Biden Administration would have to go beyond supporting the vaccines already in use in this country and need an “all of the above” approach.https://www.americanbazaaronline.com/2021/05/13/marshall-plan-meets-moonshot-445281/
        0
        • looks like that drug cova-whats-tha .. will grow hair at full speed 💥🚀
          2
          • Coming 😆lol
            2
            • 🔥 FDA very Coming 🔥
              1
              • rn you'll double your gains
                3
                • bag hodler
                  2
              • It seems like a pattern now, first few hours it will be green like 5% up and then deep red for rest of the day. :(
                5
                • yes since yesterday dropping much...covasinapproved but doesn't not look like this.another few day will be $1slowly ....hahaha
                  4
                • I do not agree on that, nor I am going to sell stocks.
                  0
              • I think this is a great time to buy.
                1
                • Vaccine effectiveness on Indian variant remain uncertain. Source WHO ... Covaxin wins big in this.💪💥💥💥
                  0
                  • thoughts on price target for today???
                    0
                    • green today
                      0
                  • thoughts on price target for today???
                    0
                    • 10.12 then 10.61
                      0
                  • thoughts on price target for today???
                    0
                    • another crazy day
                      0
                      • https://in.news.yahoo.com/double-mutant-strain-wreaks-havoc-094100983.htmlHope this news bring OCGN higher today
                        0
                        • TRIALS FOR KIDS APPROVED BY INDIAN GOVT👍🏽👍🏽👍🏽
                          0
                          • 2 - 18
                            0
                          • 0
                        • no news?
                          1
                          • yes no news...worst
                            0
                          • Worst is all up to you.
                            0
                        • dip🤡🤡
                          8
                          • Another dip
                            0
                        • dip..... 😂😂😂😂😂
                          6
                          • Evofem Biosciences EVFM Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women
                            1
                            • https://www.directorstalkinterviews.com/ocugen---consensus-indicates-potential-210.3-upside/412988015
                              0
                              • 💉 100% Against regular strain, hospitalization. 💉 100% Protects against all 4 wild strains. 💉 SAFE FOR CHILDREN. 💉 EUA IN 24 COUNTRIES . 60+ more waiting. USA NEXT. 💉 EUA IN WORKS 60+ MORE COUNTRIES. 💉 WHO APPROVAL INCOMING . (WORLD HEALTH ORGANIZATION) 💉 FDA MASTER FILE REGISTERED. 💉 TRADEMARK REGISTERED FOR US. 💉 FDA REGISTERED FOR US . (AUTOMATIC NEXT STEP IS EUA FILING) 💉 I SAY EUA FILING SOON. 💉 Potential Government Funding. 💉 Huge possibility to sell to Canada, Mexico & South America.
                                1
                                • Bharat Biotech's COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase-2 and phase-3 clinical trials on those aged between two to 18 years, official sources said.
                                  0
                                  • prob paid govt experts in India trying to promote own nation's vaccine? all useless unless approved by US FDA and sold in USA. most poor countries do not have vaccines and will take almost anything now.
                                    1
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.